SciELO - Scientific Electronic Library Online

 
vol.23 número1Purificación de anticuerpos naturales anti banda 3 de la clase IgG índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Hematología, Inmunología y Hemoterapia

versión impresa ISSN 0864-0289versión On-line ISSN 1561-2996

Resumen

AGRAMONTE LLANES, Olga et al. Irreversible aplasia due to the treatment with imatinib mesilate in a chronic myeloid leukemia: A case report. Rev Cubana Hematol Inmunol Hemoter [online]. 2007, vol.23, n.1. ISSN 0864-0289.

A 45-year-old female patient who was diagnosed chronic myeloid leukemia Ph+ in March 1984, and had treatment with busulfan, hydroxyurea, interferon and cytosine arabinoside during 15 years is presented. In March 2003, the transformation stage was diagnosed and, in April, she began to receive imatinib at daily doses of 600 mg. Evolutively, she had mild bone pain, palpebral edema and, on the 35th day, severe pancytopenia that caused the suspension of the treatment. Bone marrow samples were taken by aspiration and biopsy, and a severe medular aplasia was diagnosed. Treatment with wide-spectrum antibiotic therapy, hemoderivates, and granulocyte colony-stimulating factor was applied. In spite of these therapeutic measures, the patient died 46 days after interrupting the treatment with imatinib, with a clinical picture of irreversible medular aplasia and respiratory distress, complications attributable to Imatinib

Palabras clave : irreversible aplasia; imatinib mesylate; chronic myeloid leukemia.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons